The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio.

abstract：Background:Whole brain atrophy (WBA) estimates in multiple sclerosis (MS) correlate more robustly with clinical disability than traditional, lesion-based metrics. We compare Structural Image Evaluation using Normalisation of Atrophy (SIENA) with the icobrain longitudinal pipeline (icobrain long), for assessment of long...

journal_title：Therapeutic advances in neurological disorders

authors： Beadnall HN,Wang C,Van Hecke W,Ribbens A,Billiet T,Barnett MH

更新日期：2019-01-25 00:00:00

abstract：:A first step in evaluating the use of computers in language therapy for individuals with aphasia is to establish the treatment as active in small groups prior to large-scale clinical trials. The present study evaluated a comprehensive computer-based language therapy program in a group of eight individuals with chronic...

journal_title：Therapeutic advances in neurological disorders

authors： Archibald LM,Orange JB,Jamieson DJ

更新日期：2009-09-01 00:00:00

abstract：OBJECTIVE:Intracranial aneurysms (IAs) require deliberately selected treatment strategies as they are incrementally found prior to rupture and deleterious subarachnoid haemorrhage (SAH). Multiple and recurrent aneurysms necessitate both neurointerventionalists and neurosurgeons to optimize aneurysmal occlusion in an in...

journal_title：Therapeutic advances in neurological disorders

authors： Mueller OM,Schlamann M,Mueller D,Sandalcioglu IE,Forsting M,Sure U

更新日期：2011-09-01 00:00:00

abstract：:Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and dementia. Accumulating evidence suggests that inflammation is involved in the pathogenesis of AD. Epidemiological studies suggest that use of anti-inflammatory drugs is associated with a lower incidence of AD. However,...

journal_title：Therapeutic advances in neurological disorders

authors： Zhu M,Wang X,Sun L,Schultzberg M,Hjorth E

更新日期：2018-08-09 00:00:00

abstract：:Blepharospasm is a focal (although usually bilateral) dystonia of the orbicularis oculi muscles, producing excessive eye closure. This produces significant disability through functional blindness. Botulinum neurotoxins (BoNT) have become the treatment of choice for blepharospasm; the impressive response rate and the t...

journal_title：Therapeutic advances in neurological disorders

authors： Hellman A,Torres-Russotto D

更新日期：2015-03-01 00:00:00

abstract：:Until the early 1990s, a limited number of antiepileptic drugs (AEDs) were available. Since then, a large variety of new AEDs have been developed and introduced, several of them offering new modes of action. One of these new AED families is described and reviewed in this article. Levetiracetam (LEV) and brivaracetam (...

journal_title：Therapeutic advances in neurological disorders

authors： Steinhoff BJ,Staack AM

更新日期：2019-09-09 00:00:00

abstract：:Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase II...

journal_title：Therapeutic advances in neurological disorders

authors： Albrecht P,Bjørnå IK,Brassat D,Farrell R,Feys P,Hobart J,Hupperts R,Linnebank M,Magdič J,Oreja-Guevara C,Pozzilli C,Salgado AV,Ziemssen T

更新日期：2018-10-05 00:00:00

abstract：:Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three choline...

journal_title：Therapeutic advances in neurological disorders

authors： Yiannopoulou KG,Papageorgiou SG

更新日期：2013-01-01 00:00:00

abstract：:Natalizumab is approved for the treatment of patients with relapsing-remitting multiple sclerosis who have failed first-line treatment with traditional disease-modifying therapies or who have highly active disease. The drug has proved highly effective, both in a clinical trial setting and in clinical practice, with ma...

journal_title：Therapeutic advances in neurological disorders

authors： Fernández O

更新日期：2013-03-01 00:00:00

abstract：Background:To investigate outcome and toxicity of high-dose systemic methotrexate (HDMTX)-based polychemotherapy and intracerebroventricular (ICV) chemotherapy via an Ommaya reservoir in elderly patients with primary central nervous system lymphoma (PCNSL). Methods:We performed a retrospective analysis on patients ⩾65...

journal_title：Therapeutic advances in neurological disorders

authors： Seidel S,Kowalski T,Margold M,Baraniskin A,Schroers R,Martus P,Schlegel U

更新日期：2020-10-07 00:00:00

abstract：:More than 30% of epilepsy patients remain refractory despite the advent of new antiepileptic drugs (AEDs) over two decades. Although a small percentage of these refractory patients may become seizure free when a new AED is added, combined administration of AEDs or the application of novel AEDs is the most common thera...

journal_title：Therapeutic advances in neurological disorders

authors： Chung SS

更新日期：2010-03-01 00:00:00

abstract：Introduction:Wernicke encephalopathy (WE) and Wernicke-Korsakoff syndrome (WKS) are well-known disorders caused by thiamine deficiency. In addition to the classical concept of these diseases, some literature data suggest a connection between mitochondrial dysfunction and WE/WKS. Psychotic disorders and WKS seem to run ...

journal_title：Therapeutic advances in neurological disorders

authors： Jimoh IJ,Sebe B,Balicza P,Fedor M,Pataky I,Rudas G,Gal A,Inczedy-Farkas G,Nemeth G,Molnar MJ

更新日期：2020-07-30 00:00:00

abstract：Background:Lennox-Gastaut syndrome (LGS) is a typical intractable form of epilepsy that most often occurs between the second and sixth year of life. This study aimed to evaluate the clinical efficacy and safety of ketogenic diet therapies (DTs) for LGS with mitochondrial dysfunction. Methods:This was a retrospective s...

journal_title：Therapeutic advances in neurological disorders

authors： Na JH,Kim HD,Lee YM

更新日期：2020-02-06 00:00:00

abstract：:Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy has been considered a novel central nervous system autoimmune disease characterized by relapse and responsiveness to corticosteroid with a specific GFAP-Immunoglobulin G (IgG) being noted in cerebrospinal fluid. We report the case of a 21-year-old girl p...

journal_title：Therapeutic advances in neurological disorders

authors： Li XL,Han J,Zhao HT,Long YM,Zhang BW,Wang HY

更新日期：2020-06-03 00:00:00

abstract：Background:To compare the long-term clinical outcomes of different antihypertensive drugs in stable patients after acute hemorrhagic stroke (HS). Methods:From January 2001 to December 2013, patients with first-ever primary HS were identified in the National Health Insurance Research Database, Taiwan. Patients with tra...

journal_title：Therapeutic advances in neurological disorders

authors： Liu CH,Lin YS,Chi CC,Liou CW,Lee JD,Peng TI,Lee TH

更新日期：2018-09-28 00:00:00

abstract：Background:Network science provides powerful access to essential organizational principles of the brain. The aim of this study was to investigate longitudinal evolution of gray matter networks in early relapsing-remitting MS (RRMS) compared with healthy controls (HCs) and contrast network dynamics with conventional atr...

journal_title：Therapeutic advances in neurological disorders

authors： Fleischer V,Koirala N,Droby A,Gracien RM,Deichmann R,Ziemann U,Meuth SG,Muthuraman M,Zipp F,Groppa S

更新日期：2019-04-24 00:00:00

abstract：:Experimental models of Parkinson's disease (PD) are of great importance for improving the design of future clinical trials. Various neurotoxic models are available, including 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat and rotenone. However, no model is considered perfect;...

journal_title：Therapeutic advances in neurological disorders

authors： Salama M,Arias-Carrión O

更新日期：2011-11-01 00:00:00

abstract：OBJECTIVES:To assess clinical outcomes and patient satisfaction in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were switched from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG). METHODS:Eight consecutive patients, four...

journal_title：Therapeutic advances in neurological disorders

authors： Hadden RD,Marreno F

更新日期：2015-01-01 00:00:00

abstract：:Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) have been the first class of specifically developed preventive treatments for migraine. Clinical trials data suggest superiority of the CGRP mAbs to placebo in terms of prevention of migraine symptoms, migraine-specific quality of life and headache re...

journal_title：Therapeutic advances in neurological disorders

authors： Andreou AP,Fuccaro M,Lambru G

更新日期：2020-05-27 00:00:00

abstract：:The treatment of neuropathic pain is difficult. Oral pharmaceuticals have significant side effects, and treatment efficacy tends to be modest. The use of topical analgesics reduces the potential for systemic side effects and allows direct application of medications to the area of pain. The natural spicy substance, cap...

journal_title：Therapeutic advances in neurological disorders

authors： Peppin JF,Pappagallo M

更新日期：2014-01-01 00:00:00

abstract：:Laquinimod is a novel immunomodulatory agent, in development as a potential disease-modifying treatment for multiple sclerosis (MS). Structurally related to linomide, its pharmacological predecessor, laquinimod combines anti-inflammatory and possibly clinically relevant neuroprotective effects with the convenience of ...

journal_title：Therapeutic advances in neurological disorders

authors： Haggiag S,Ruggieri S,Gasperini C

更新日期：2013-11-01 00:00:00

abstract：Background:Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods:Levels of C3, C4, C5a, and ...

journal_title：Therapeutic advances in neurological disorders

authors： Aguirre F,Manin A,Fernandez VC,Justo ME,Leoni J,Paz ML,Villa AM

更新日期：2020-08-10 00:00:00

abstract：:Superficial temporal artery-middle cerebral artery anastomosis is generally considered as an effective method in improving damage associated with intracerebral occlusions in moyamoya disease. Hemodynamic changes caused by revascularization are the cause of many postoperative complications. Of the 186 consecutive surge...

journal_title：Therapeutic advances in neurological disorders

authors： Yu J,Hu M,Yi L,Zhou K,Zhang J,Chen J

更新日期：2019-09-25 00:00:00

abstract：:Cluster headache (CH) is a short-lasting unilateral headache associated with ipsilateral craniofacial autonomic manifestations. A positron emission tomography (PET) study has shown that the posterior hypothalamus is activated during CH attacks, suggesting that hypothalamic hyperactivity plays a key role in CH pathophy...

journal_title：Therapeutic advances in neurological disorders

authors： Leone M,Franzini A,Cecchini AP,Broggi G,Bussone G

更新日期：2010-05-01 00:00:00

abstract：BACKGROUND:The aim of this study was to analyse registry data of seizure outcome and adverse events (AEs) for perampanel as add-on therapy in patients with focal epilepsy since its approval in 2012 for adjunctive treatment of focal epilepsy in patients ⩾12 years. METHOD:A retrospective 2-year chart review of all patie...

journal_title：Therapeutic advances in neurological disorders

authors： Rohracher A,Kalss G,Leitinger M,Granbichler C,Deak I,Dobesberger J,Kuchukhidze G,Thomschewski A,Höfler J,Trinka E

更新日期：2016-11-01 00:00:00

abstract：Background:No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing-remitting multiple sclerosis (RRMS). Objective:To assess the NEDA status of...

journal_title：Therapeutic advances in neurological disorders

authors： Arnold DL,Shang S,Dong Q,Meergans M,Naylor ML

更新日期：2018-08-28 00:00:00

abstract：:B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and production of autoantibodies directed against myelin. Hence, the usage of B-cell-depleting monoclonal antibodies as therapy for autoimmune...

journal_title：Therapeutic advances in neurological disorders

authors： Sorensen PS,Blinkenberg M

更新日期：2016-01-01 00:00:00

abstract：:In the past few years, acquired demyelinating syndromes of the central nervous system associated with antibodies against myelin oligodendrocyte glycoprotein (MOG) have evolved into a new inflammatory disease entity distinct from neuromyelitis optica spectrum disorders or multiple sclerosis. The meticulous clinical des...

journal_title：Therapeutic advances in neurological disorders

authors： Hegen H,Reindl M

更新日期：2020-07-31 00:00:00

abstract：:Stroke is the fifth leading cause of death and the most frequent cause of disability worldwide. Currently, stroke diagnosis is based on neuroimaging; therefore, the lack of a rapid tool to diagnose stroke is still a major concern. In addition, therapeutic approaches to combat ischemic stroke are still scarce, since th...

journal_title：Therapeutic advances in neurological disorders

authors： Ramiro L,Simats A,García-Berrocoso T,Montaner J

更新日期：2018-08-06 00:00:00

abstract：Background:Gastrointestinal (GI) events are common adverse events (AEs) associated with delayed-release dimethyl fumarate (DMF), an approved treatment for relapsing-remitting multiple sclerosis (RRMS). The objective of the TOLERATE study was to evaluate GI tolerability and GI mitigation via symptomatic therapies in pat...

journal_title：Therapeutic advances in neurological disorders

authors： Gold R,Schlegel E,Elias-Hamp B,Albert C,Schmidt S,Tackenberg B,Xiao J,Schaak T,Salmen HC

更新日期：2018-04-18 00:00:00